Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revive Therapeutics Ltd. C.RVV

Alternate Symbol(s):  RVVTF

Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is... see more

Recent & Breaking News (CSE:RVV)

Revive Announces Completion of Rights Offering for Gross Proceeds of $844,693 to Fund the Clinical Development of Bucillamine for the Treatment of Cystinuria

MarketWire Canada June 20, 2016

Revive Announces $1,500,000 Best-Efforts Non-Brokered Private Placement

MarketWire Canada May 30, 2016

Revive Therapeutics Appoints Tessio Rebello, Ph.D. as Clinical Advisor

Marketwired April 19, 2016

Revive Therapeutics Ltd Announces Results for the Three and Six Months Ended December 31, 2015

Marketwired February 26, 2016

Revive Therapeutics Announces Issuance of U.S. Patent Related to Bucillamine in the Treatment of Gout

Marketwired January 20, 2016

Revive Therapeutics to Present at Noble Capital Markets' Investor Conference

Marketwired January 19, 2016

Revive Therapeutics Announces DTC Eligibility of Its Common Shares

Marketwired December 8, 2015

Revive Therapeutics Retains the Ruth Group to Build U.S. Investment Community Awareness

Marketwired December 7, 2015

Revive Therapeutics Announces Positive Final Results from Its Phase 2a Study for the Treatment of Acute Gout Flares

Marketwired December 1, 2015

Revive Therapeutics Ltd. Announces Results for the Three Months Ended September 30, 2015

Marketwired November 26, 2015

Revive Therapeutics Announces Listing on the OTCQB Market Exchange

Marketwired November 25, 2015

Dr. Lee S. Simon Joins Revive Therapeutics as Senior Clinical and Regulatory Affairs Advisor

Marketwired November 18, 2015

Revive Therapeutics Announces US FDA Grants Orphan Drug Designation for Bucillamine for the Treatment of Cystinuria

Marketwired October 26, 2015

Revive Therapeutics Ltd. Announces Results for Fiscal Year Ended June 30, 2015

Marketwired October 21, 2015

Revive Therapeutics Announces Positive Interim Results From Phase 2a Study of REV-002 (Bucillamine) in the Treatment of Acute Gout Flares

Marketwired September 30, 2015

Revive Therapeutics Announces Results for the Three and Nine Months Ended March 31, 2015

Marketwired May 20, 2015

Revive Therapeutics to Present at Marcum MicroCap Conference

Marketwired May 4, 2015

Revive Therapeutics Announces Positive Study Results From Its Research Collaboration With Rettsyndrome.org

Marketwired April 27, 2015

Bruce N. Cronstein, MD. Joins Revive Therapeutics as Medical Advisor

Marketwired April 15, 2015

Revive Therapeutics Enters Into Advisory Agreement with Spinnaker Capital Markets Inc.

Marketwired March 5, 2015